<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01964703</url>
  </required_header>
  <id_info>
    <org_study_id>ED13024</org_study_id>
    <nct_id>NCT01964703</nct_id>
  </id_info>
  <brief_title>Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes</brief_title>
  <official_title>Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes; A Proof-of-concept, Randomized, Double-blind, Parallel-group Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University Anam Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Rubus occidentalis extract could improve
      fasting or postprandial serum glucose levels, and related metabolic markers among patients
      with prediabetes (impaired fasting glucose and/or impaired glucose tolerance).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum glucose (fasting and post 75g oral glucose tolerance test)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum insulin</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>HOMA IR, QUICKI, HOMA beta, lipid profile, inflammatory markers</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Prediabetes (Impaired Fasting Glucose and/or Impaired Glucose Tolerance)</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rubus occidentalis extract 900mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>taking Rubus occidentalis extract 900mg/day for 12weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rubus occidentalis extract 1800mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>taking Rubus occidentalis extract 1800mg/day for 12weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rubus occidentalis extract</intervention_name>
    <arm_group_label>Rubus occidentalis extract 900mg</arm_group_label>
    <arm_group_label>Rubus occidentalis extract 1800mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  19 years of age or older

          -  prediabetes (fasting plasma glucose 100-125mg/dl, and/or post 75g OGTT plasma glucose
             140-199mg/dl)

        Exclusion Criteria:

          -  pregnant women

          -  taking anti-hyperglycemic agents within 3 months at the time of enrollment

          -  history of heart failure, myocardial infarction, cerebral infarction

          -  uncontrolled hypertension (systolic BP &gt; 160mmHg, or diastolic BP &gt; 100mmHg)

          -  serum triglyceride level &gt; 500mg/dl

          -  kidney dysfunction (serum Creatinine &gt; 30% of upper normal limits)

          -  hepatic dysfunction (AST, ALT &gt; 3 times of upper normal limits)

          -  taking systemic glucocorticoids within 1 month
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2013</study_first_submitted>
  <study_first_submitted_qc>October 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2013</study_first_posted>
  <last_update_submitted>October 14, 2013</last_update_submitted>
  <last_update_submitted_qc>October 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Anam Hospital</investigator_affiliation>
    <investigator_full_name>Sin Gon Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

